Drug intelligence / Profile preview

BMS-741672

Development stage: Phase 2
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-741672 is a selective, orally active small molecule antagonist of the C-C chemokine receptor type 2 (CCR2), developed by Bristol Myers Squibb. It demonstrates high selectivity for CCR2 over CCR5 (>700-fold), with potent inhibition of monocyte chemotaxis in vitro (IC50 ~0.67–1.1 nM). The drug was advanced into clinical trials for insulin resistance and related metabolic disorders, reaching up to Phase II development. Preclinical studies showed good oral bioavailability and safety margins in animal models[1][3][5][7].

Other names: N-(5-(isopropyl(methyl)amino)-2-(2-oxo-3-((6-(trifluoromethyl)quinazolin-4-yl)amino)pyrrolidin-1-yl)cyclohexyl)methanesulfonamide

Targets

CCR2 (Chemokine (C-C motif) Receptor 2)

Beyond the preview

Go deeper on BMS-741672.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-741672.

Explore the full profile